Samphire Neuroscience

Samphire Neuroscience operates at the intersection of women’s health, medical devices, digital therapeutics, and consumer wellness. Its differentiation is the application of non-invasive brain stimulation to conditions that are often addressed through hormonal treatment, surgery, or general symptom management. Nettle™ is positioned as a CE-marked, drug- and hormone-free device for menstrual-cycle-related pain, mood, and functional limitations, while Lutea™ extends the same underlying stimulation approach into wellness, recovery, sleep, and stress regulation. The Samphire App and CycleSync™ AI are intended to personalize device use for women, creating a software layer around the hardware. Relative to general wearable wellness companies, Samphire emphasizes clinical validation, regulated-device positioning, ISO 13485 certification, and condition-specific neurostimulation. Relative to conventional women’s-health therapeutics, its proposed advantage is a non-pharmacological intervention that can be used alongside training, recovery, and daily health routines.

Samphire Neuroscience shows a progression from early research and product development toward regulated commercialization. The company was founded in September 2021 and recorded three pre-seed financings between December 2021 and February 2024, alongside a convertible note dated May 25, 2023 and non-equity assistance from PharmStars dated Jun 20, 2023. The main inflection point was the $5 million seed round announced on Jun 3, 2025, which increased cumulative recorded funding to $7.3 million and added a broad group of institutional and individual investors. Product development has also advanced from the Nettle™ neuromodulation device to a broader platform that includes the Samphire App, CycleSync™ AI, and Lutea™ for wellness use. Nettle’s CE-marked status and reported clinical benefits provide a foundation for commercialization, while the company’s hiring for clinical partnerships, commercial business development, and medical science liaison positions suggests an effort to convert clinical evidence into distribution and adoption. Employee-count data remains broad, limiting precision on operating scale.